We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Spartan Bioscience Announces Strategic Investment from Canon U.S.A.

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Spartan Bioscience Inc. has received a strategic investment from Canon U.S.A., Inc., a leader in digital imaging solutions. As part of the investment, Seymour Liebman will be joining Spartan’s Board of Directors. Mr. Liebman is executive vice president, chief administrative officer and general counsel of Canon U.S.A., Inc., senior executive officer of Canon Inc., vice chairman of Canon Solutions America, Inc. and is a member of the Board of Directors of Canon BioMedical, Inc., a recently established wholly-owned subsidiary of Canon U.S.A., Inc.

In addition to the strategic investment, Canon BioMedical and Spartan Bioscience plan to explore areas to work together on the development of future diagnostic products.

“We are delighted to welcome Canon U.S.A. as a strategic investor in Spartan Bioscience,” said Paul Lem, M.D., CEO of Spartan Bioscience. “Spartan is forging new markets for rapid genetic testing, and we are excited to accelerate our progress with this investment.”

“Canon is excited to make this investment in Spartan Bioscience and I am also honored to join the Board of Directors,” said Liebman. “With the recent establishment of Canon BioMedical, it is a natural fit for us to explore areas with Spartan to uncover new diagnostic testing methods that can help benefit the health of future generations.”